TY - JOUR
AR - ACO-2019-1-101
TI - Deaminases and Why Mice Sometimes Lie in Immuno-Oncology Pre-Clinical Trials?
AU - Edward J., Steele 
AU - Robyn A. , Lindley
JO - Annals of Clinical Oncology
PY - 2019
DA - Tue 30, Apr 2019
SN - 2674-3248
DO - http://dx.doi.org/10.31487/j.ACO.2019.01.001
UR - https://www.sciencerepository.org/deaminases-and-why-mice-sometimes-lie-in-immuno-oncology-pre-clinical-trials_ACO-2019-1-101 
KW - Cytosine and adenosine deaminase, immuno-oncology pre-clinical trials cancer progression combinatorial association somatic hypermutation
AB - There is now much evidence for the involvement of deaminase-mediated somatic mutagenesis during cancer
progression. These developments lead us to reappraise the likely impact of AID/APOBEC and ADAR
deaminases in human cancer progression with their expected lesser impact on somatic mutagenesis in mouse
cancer model systems. The findings are important for pre-clinical trials of immune oncology (IO) drugs
activating adaptive immune responses against tumor cells. Our conclusions are consistent with, and
underline, recent recommendations by Decker and colleagues that IO pre-clinical trials should at least
include therapies against spontaneous tumors in dogs. While the AID/APOBEC deaminase specificity
repertoire in dogs is likely to be less than in humans, it will be far greater than in the mouse and thus more
likely to better mimic dysregulated Ig like somatic hypermutation responses during cancer progression in
humans.